SARS-CoV-2–Fighting T Cells Found in Recovered Patients

While the finding doesn’t prove people become immune to the virus after infection, it is good news for vaccine development.

Shawna Williams

| 2 min read

an image of a molecule with three intertwined components

Listen with Speechify

0:00

2:00

ABOVE: The SARS-CoV-2 spike protein
© ISTOCK.COM, VDVORNYK

Even as researchers around the world rush to develop a vaccine against the virus that causes COVID-19, and some pin their hopes on the idea that enough people will recover from infections to achieve herd immunity in the meantime, questions about whether exposure to the virus induces immunity to it have lingered. If the virus itself does not prompt immunity, a vaccine against it might not either.

Although it doesn’t provide a conclusive answer, a study published yesterday (May 14) in Cell appears to be good news on the immunity front. Researchers at the La Jolla Institute for Immunology in California took blood from 20 adults who’d recovered from COVID-19 and exposed the samples to proteins from the SARS-CoV-2 virus. All of the patients had CD4+ helper T cells that recognized the virus’s spike protein, and 70 percent of them had CD8+ killer ...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!

Join for free today

Already a member? Login Here

Keywords

Meet the Author

Shawna Williams
Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor's degree in biochemistry from Colorado College and a graduate certificate and science communication from the University of California, Santa Cruz.
View full profile